N-(2-SUBSTITUTED ALKYL)-N'-[(IMIDAZOLE-4-YL)ALKYL]GUANIDINE

Abstract: N-(2-substituted alkyl)-N'-[(imidazole-4-yl)alkyl]guanidines having formula (1), wherein m is 1, 2 or 3; n is 2 or 3; X is a) S, O or CH2, and Y is a R substituted diphenylmethyl group or (10,11-dihydro)5H-dibenzo-[a-d]-cycloheptene-5-yl group, or is b) formula (II), wherein Y1 is a R-substituted phenyl group and Y is also a R-substituted phenyl group in that Y and Y1 need not be substituted simultaneously or Y is a R-substituted benzyl group, or is c) =CH-, and Y is a R-substituted diphenylmethylidenyl group or (10,11-dihydro)-5H-dibenzo-[a,d]-cycloheptene-5-ylidene group, R is H, alkyl, alkoxy halogen and/or trihalogen methyl, with the understanding that from all the appropriate phenyl rings one or more may be substituted by a R-substituted heterocyclic aromatic ring and their addition salts, with activity against heart failures and allergic conditions.

Description: N-(2-substituted alkyl)-N'-/imidazole-4-yl)alkyl? guanidine. The invention ralates to a N- (2-substituted alkyl)-N'-/7imidazole- 4-yl) alkyl/guanidine. Impromidine, or N-/2-(5-methylimidazole-4-yl methylthio)ethyl/-N'- /3- (imidazole-4-yl)propyl/guanidine is known as a specific and the most potent histamine H -agonist, Dependent on the used test system it either behaves like a partial or like a complete agonist having a potency of 5-800 times that of histamine (Proc. Vlllth Internat. Symp. Med. Chem. Uppsala, pages 202-203 (1985) Eds R.Dahlbom and J.L.G. Nilsson) . Because of its effect on the release of histamine from mast cells, there might be some use of impromidine in the treatment of allergic conditions. However, a major drawback for the clinical use of impromidine is its relatively high potency in stimulating the gastric acid secretion and its effect on vasoconstriction and vasodilation. Now a series of new impromdine-related compoundswas discovered, said compounds having a high histamine H -agonistic acitivity on the guinea-pig right atrium with a relatively low activity on the guinea-pig gastric acid secretion and a potent histamine H -anta¬ gonism as tested on both the guinea-pig ileum and the guinea-pig trachea.Because of this combination of histamine H -antagonism and H -agonism in one compound, these compounds are of clinical significance for e.g. the treatment of congestive heart failures and some allergic conditions. These new compounds are N- (2-substituted alkyl) -N 1 -/imidazole-4- yl)alkyl/guanidines of formula 1, wherein: m is 1, 2 or 3; n is 2 or 3; X is a) S, O or CH„, and Y is a R substituted diphenylmethyl group or (10,11-dihydro) 5H- dibenzo-/a-d7-cycloheptene-5-yl group, or is b) N , wherein I Y l Y is a R-substituted phenyl group and Y is also a R-substituted phenyl group in that Y and Y. need not be substituted simultaneously or Y is a R-substituted benzyl group, or is c) =CH-, and Y is a R-substituted diphenylmethylidenyl group or (10,11-dihydro)-5H-dibenzo-/a,d?-cycloheptene-5-ylidene group, R is H, alkyl, alkoxy, halogen and/or trihalogen methyl, with the understanding that from all appropriate phenyl rings one or more may be substituted by a R-substituted heterocyclic aromatic ring and their acid addition salts. Possibly present R-substituted heterocyclic aromatic rings are for example: 2-, 3- and 4-pyridinyl, 4-imidazolyl, 4-thiazolyl, 2-guanidino-4-thiazolyl, 2- and 3-furanyl, 2-dimethylaminomethyl- 5-furanyl, etc. The results of pharmacological tests with said new compounds are summarized in Table A (H -activity) and Table B (H -activity) . The values for the H,-activity given are the mean of at least two experiments in quadruplo, while the values for the H -activity result from at least two experiments in duplicate. In Table A the tested compounds are defined by a formula, and the meaning of R and n in the formula are stated in the table. In addition the compound have serial.numbers corresponding with the serial numbers used in Table B. It is remarked that the last three compounds in the two tables do not fall within the invention, but are stated for comparison. SUBSTITUTE SHEET TatleA Histaπinp ? - activi ty H H ll i-n /- NH HN N continuation of table \ XIII Impromidine 5,5 not determined XIV Diphenhydramine 8,0 not determined Table B Histamine H-,- activity atrium gastric fundus C-: pD (±0,1) 10 x pD,(±0,2) I 1,0 6,8 1,0 6,1 II 0,3 4,8 0,5 4,9 III 0,9 5,5 0,4 15 * 5,8 IV 0-,8 -5,9 . not determined V 0 4,0 0 4,0 VI 0,8 5,9 0,4 5,5 VII 0,3 5,9 0 not determined VIII 0,9 5,6 0 5,0 IX 1,0 7,7 not determined X 1,0 7,0 0,9 5,6 25 XI 1,0 6,4 0,7 6,5 XII 1,0 7,2 1,0 7,6 XV His amine 1,0 6,1 1,0 ' 5,5 0 XIII Impromidine 1,0 7,8 1,0 8,5 Discussion H -activity There is no change in H.-activity when changing the 5-methyl- i idazole part of impromidine in a phenyl group (compound XII) . However, introducing an extra phenyl group in compound XII results in an increase in pA_ from 5.5 to 6.5 (Compound I) on the guinea-pig ileum. Shortening the trime h lene chain in compound I to an ethylene chain (compound II) has no effect on the H.-activity. Analogous results have been obtained when comparing compound IV with compound V and compound VIII with compound IX. Substituting an oxygen for the sulphur atom (compound III) turned out to be ten times as potent as the starting compound on the guinea-pig ileum and even 25 times as potent on the trachea. Introducing a parametnyl group (compounds IV and V) or a parafluoro group (compound VI) has only little or no effect at all on the H -antagonism. Also compounds ' VII, VIII, IX and X are almost as potent H -antago¬ nists as compound I. Compound XI seems to be even a slightly more potent H -antagonist than the oxygen analogue compound II. — H„-activitv Replacing the 5-methylimidazole group of impromidine by a phenyl group (compound XII) is attended with a 4-fold decrease in H -activity on the guinea-pig atrium and an 8-fold decrease on the gastric fundus. Introduction of an extra phenyl group in compound XII (compound I) results in a 2 a 3 fold reduction in H_-agonism on the atrium and even 32-fold decrease in H' -agonism on the fundus. Shortening the trimethylene chain of compound I to an ethylene chain (compound II) results in a marked decrease in H -activity, both on the atrium and on the fundus. Analogous results have been obtained with the compound IV with regard to compound V and the compound VIII with regard to compound IX. Replacing the sulphur atom in compound I by .an oxygen atom (compound III) results in a 20-fold decrease in H„-agonism on the atrium. On the gastric fundus the change in pD is less pronounced but in this test system this change in structure is attended with a remarkable decrease in intrinsic activity. Also introduction of a para methyl group (compounds IV and V) or a para fluor group (compound VI) results in a strong decrease in H -activity. Compound VII was found to be an almost as potent H„-antagonist as the para methyl and fluoro analogues. When the sulphur atom in compounds I and II is omitted, the diphenylpropyl analogues, compounds VIII ana IX are obtained. These compounds show a remarkable high potency on the guinea-pig right atrium. Compound IX was found to be almost as potent as impromidine on the atrium. Introduction of a double bond (compound X) results in a 4-fold decrease in H_-activity on the atrium. The amino analogue, compound XI, proved to be about twice as potent as histamine on the atrium and to have about 4% of the activity of impromidine in this test system. On the gastric fundus this compound has about 1% of the activity of impromidine and 10 times the activity of histamine. Conclusions The oxygen analogue, compound III, and the amino analogue, ccoommppoouunndd XXII,, ttuurrnneedd oouutt ttoo bbee tthhee mmoos=t potent H -antagonists o: this series of impromidine analogues. Compounds I, IX and X proved to be the most potent compounds of this series on the guinea-pig right atrium. Because of their combination of qualities compounds I, IX, X and XI are the most preferred compounds. The pharmacological tests were carried out as follows: Guinea-pig trachea (H ) Male guinea-pigs (350-500 g) were killed by a blow on the head and the trachea removed. Single segments were cut from the trachea, loaded with 0.4 g and placed in an organ bath (35 C) containing 120 mM NaCl, 6 mM KC1, ImM MgSO , 2.5 mM * CaCl_, lir. NaH^PO , 2.5 mM NaHCO., and 6 mM glucose. The organ bath was gassed with oxygen containing S i CO . PD , intrinsic acitivity and antagonistic activity of the test compounds were determined from isotonically recorded, cumulative dose-response curves. The H -specificity of the organ has been established by blocking the histamine induced contractions of the trachea with mepyraπine. Moreover, both the specific histamine H -agonist dimaprit -3 (UD to 10 M) and the soecific histamine H„-antagonist cirnet dine (up to 10 M) proved to have neither effect on the resting state of the organ nor on the histamine induced contractions . Guinea-pig ileum (H.) Histamine H -activity at the guinea-pig ileum has been determined as described by Emmett et al. J.Med.Chem., 25_, 1168-1174 (1932). Guinea-pig right atrium H,. Histamine H -activity at the guinea-pig right atrium has been determined as described by Sterk et al. Eur.J.Med. - Chim.Ther., 19_, 545-550 (1984) . Guinea-pig gastric acid secretion (H„) Histamine H„-activity at the acid secretion of the isolated gastric fundus of the guinea-pig has been determined as described by Impicciatore et al. Eur. J. Pharmacol., 48, 249-254 (1975). Synthesis The present compounds are prepared according to reaction scheme A or B. In these reaction schemes R corres∞nds with the grouo x Y-X-(CH 2 )m - of formula 1. The primary amines used in step 1 and step 5, were prepared according to methods described in ^ the literature or were commercially available (3.3-diphenyl propylamine) . The reaction of the primary amines with benzoylisothiocyanate to the benzoyl thiourea derivatives (step 1) proceeded with high yields (66-88°) . The hydrolysis of these benzoylthioures derivatives (step 2) also proceeded with high yields (30-93°s) . The isothioureas resulting from the reaction of the thioureas with methyl iodide (step 3) were not isolated, but reacted directly, after evaporating the excess of methyl iodide, with 4-(3-aminopropyl) imidazole or 4-(2-aminoethyl) imidazole (step 4) . The last reaction gave only poor yields (8-30%)no matter how long the reaction time (up to 140 hours refluxing in propanol-1) . The compounds with a basic group in the 'R part' (compounds VII and XI) were synthesized via their corresponding cyano-guanidine. The primary amines were first reacted with dimethyl-cyanoimino- dithiocarbonate (step 5) . This reaction proceeded very well and resulted in high yields of the isothioureas (about 70%) . These N-cyanoisothioureas were reacted with 4- (3-aminopropyl) imidazole to the cyanoguanidines (step 6) . This reaction gave only very poor yields (10-20%) . Also in this case no increase in yield could be observed when increasing the reaction time beyond 70 hours. The hydrolysis of these cyanoguanidines to the end products (compounds VII and XI) gave an almost quantitative yield. These products were purified as their tripicrates in order to remove the ammoniumchloride formed in this hydrolysis. Svnthesis of the amines 2-(diphenylmethylthio)ethylamine, HC1. ( ,) This compound is prepared according to R.G. Hiskey and M.A. Harpold Tetrahedr., 23, 3923-3929 (1967). 2- (diphenylmethoxy)ethylamine.maleic acid (A ) This compound is prepared according to Van der Stelt et al. Arznei itt.Forsch. l l_, 1446-1449 (1967) . General process for the synthesis of 2-/alpha-phenyl-4-methyl- benzylthio/ethylamine {A ) and 2-/alpha-phenyl-4-fluorbenzylthio/ ethv-la ine.HC ,l (A t x.—) Compounds A and A are prepared analogous to the method mentioned for the preparation of compound A . A solution of 0.2 mole of the desired substituted benzhydrol, 0.2 mole of cysteamine and 28 ml of borontrifluoride etherate in 200 ml of acetic acid was refluxed for one hour. After cooling the solution was evaporated and the residue crystallized from 2-propanol/ether. Results : A : the free base was distilled under reduced pressure, boiling point : 115-120 C. o melting point of the dihydrcgen maleate : 125-128 C. yield: 86% • ^- MR: (CDC1 / free base) : 3 1.32 ppm, singlet, 1.8 H; 2.28 ppm, singlet, 3.OH; 2.36-2.94 ppm, multiplet, 4.0 H; 5.12 ppm, singlet, l.OH; 6.77-7.60 ppm, multiplet, 9.3 H. A.: melting point 144-148 C yield: 92% ^-NMR (CDC1 , free base) : 1.28 ppm, singlet, 2.0H; 2.35-2.98 ppm, multiplet, 4.0 H; 5.12 ppm, singlet, 1.0 H; 6.76-7.54 ppm, multiplet, 9.2 H. 3.3-disnenvlDroD-2-envlamme, HC1 (A_) This compound can be prepared according to Jones et al. J.Med.Chem., _14_, 161-164 (1971) . 3.3-diohenv oroDvlamine (A,) This compound is commercially available. N-benzyl-N-ohenylethylenediamine.HCl (A ) This compound is prepared according to US-A- 2 505 133. General orocedure_for_the_oreDaration of the benzovlthioures derivatives _(B ;_5< ) A solution of about 20 g of the free base of the corresponding amine (A - A ) in 100 ml of CHCl was added slowly to a solution l 3 of an equimolar amount of benzoylisothiocyanate in 100 ml of CHCl . The resultant solution was refluxed for 15 minutes and subsequently concentrated under reduced pressure to approximately 50 ml. Addition of diethyl ether caused BAD ORIGINA crystallisation. The precipitate was filtered off, washed with ether and dried. ^^ϋ EΞϊil^ll/Ili^-:?! ® !}!-: 111 ^thylthio ) _ethyl/thiourea ( B ) Yield: 88% melting point : 101-103°C 1 H-NMR(CDC1 ) :2.70 ppm, triplet, J = 6.0 Hz, 2.1 H; 3.78 ppm, quartet, J = 6.0 Hz, 2.0 H; 5.26 ppm, singlet, 1.0 H; 7.04 - 7.96 ppm, multiplet, 16.0 H; 8.96 ppm, singlet (b) , 0.9 H; 10.9 ppm, triplet (b) , J = 5.8 Hz, 0.9 H. N-benzoyl-N'-/2- (diphenylmethoxy)ethvl/thiourea (B„) Yield: 87% melting point: 123-125 C ■ "Ή-NMR (CDCl ) : 3.60 ppm, triplet, J = 5.5 Hz, * 2.0H; 3.90 ppm, quartet, J = 5.4 Hz, 2.0 H; 5.34 ppm, singlet, 1.0 H; 7.02-7.33 cprπ, multiplet, 15.0 H; 3.38 ppm, singlet (b) , Z , ?.H; 11.00 ppm, singlet (b) , 0.9 3. N-benzoyl-N'-2-/alp a-phenyl-4-m thylbenzylthio/ th lthiourea i3_,) Yield: 87% oil, purified by column chromotography (silica 0.063-0.20Cmm, chloroform) H-NMR (CDCl,) : 2.29 ppm, singlet, 3.0 H: 2.70 ppm, triplet, J = 6.0 Hz, 2.0 H; 3.77 ppm, quartet, J = 6.0 Hz, 2.0 H; 5.26 ppm, singlet, 1.0 H: 7.02-7.94 ppm, multiplet, 15.0 H; 8.94 ppm, singlet (b) , 0.9 H; 10.2 ppm, triplet (b) . J = 5.6 Hz, 0.9 H. N-benzoyl-N'~/2- (alpha-phenyl-4-fluorobenzylthio) ethyl7~thiourea Yield: 70% SUBSTITUTE SHEET melting point: 99-102 C ^-NMR (CDCl ) : 2.70 ppm, triplet, J = 5.9 Hz, 1.9 H; f ' 3.34 ppm, quartet, J = 5.9 Hz, 1.3 H; 5.29 ppm, singlet, 0.9 H; 6.74-7.93 ppm, multiplet 14.7 H; 8.97 ppm, singlet, 0.8 H; 10.38 ppm, triplet, J = 5.9 Hz, 0.9 H. N-benzoyl-M'- (3.3-diDhenylproo-2-enyl) thiourea (B ) _^_ '_ _ _ 5 Yield: 35% melting point: 140-141 C ^-NMRtCDCl ) : 3.62-3.85 ppm, disturbed quartet, 1.7 H; 5.59 ppm, triplet, J = 7.1 Hz, 0.9 H; 6.38-7.29 ppm, multiplet, 15.6 H; 8.31 ppm, singlet, O.y H; 10.08 ppm, singlet, 0.8 Hz. „ -benzoyl-N 1 - (3 .3-diphenylprσpyl) thiourea (B,.) o Yield : 66 % melting point: 116-118 C ^-NMRCCDCl ) : 2.47 ppm, quartet, J = 7.4 Hz, 1.3 H; 3.64 ppm, quartet, J = 7.4 Hz, 1.8H; 4.02 ppm, triplet, J = 7.4 Hz, 1.0 H; 7.00-7.90 ppm, multiplet, 15.7 H; S.91 ppm, singlet, 0.3 H; 10.68 ppm, singlet, 0.3 H. General procedure for the oreparatio] of thioureas (C, - .) . 1 6 A solution of 25 g of a benzoylthiourea (B -B,.) in a mixture 1 6 of 200 ml acetone and 200 ml ethanol was added slowly to a solution of 25 g K CO in 200 ml H O at 30°C. The resultant mixture was refluxed for 2 hours. After concentrating the mixture under reduced pressure the thiourea analogue {C. -C r ) crystallized. 1 6 N-/ 2- (diphenylmethylthio)ethyl7thiourea (C ) Yield: 86% melting point: 67-70 C SUBSTITUTE SHEET 1 H-NMR(CDC1 ) : 2.60 ppm, triplet, J = 6.3 Hz, 2.0 H; 3.50 ppm, singlet (b) , 2.0 H; 5.22 ppm, singlet, 1.0 H; 6.00 ppm, singlet, 2.OH; 6.90 ppm, triplet (b) , J = 6.0 Hz, 0.9 H; 7.14-7.56 ppm, multiplet, 10.OH. N-/2- (diphenylmethoxy)ethyl?thiourea (C„) Yield: 87% melting point: 128-130°C 1 H-NMR (CDC1 ) : 3.08-3.90 PPm, multiplet (b) , 4.0 H; 5.36 ppm, singlet, 1.0 H; 6.00-6.70 ppm, broad signal, 2.0 H; 7.30 ppm, singlet, 11.4 H. N-/2- (alpha-phenyl-4-methylbenzylthio)ethyl/thiourea (C ) Yield: 85% melting point: 115-117°C ^-NMR (DMSO-d : 2.29 ppm, singlet, 3.1 H; 2.53 ppm, triplet, J = 5.4 Hz, 2.1H; 3.10-3.30 ppm, multiplet, 2.OH; 5.16 ppm, singlet, 1.0 H; 5.90 ppm, singlet, 1.3 H; 6.79 ppm, triplet, J = 7.2 Hz, 1.0 H; 7.30-7.56 ppm, multiplet, 11.0 H. N-/2- (alpha-phenyl-4-fluorobenzylthio)ethyl?thiourea (C ) — — 4 Yield: 30ϊ melting point: 101-105 C 1 H-NMR (CDC1 ) : 2.25 ppm, triplet, J = 5.4 Hz, 2.0 H; 3.02-3.92 ppm, multiplet, 2.0 H; 5.22 ppm, singlet, 2.0 H: 6.11 ppm, singlet, 1.3 H; 6.76-7.53 ppm, multiplet, 10.4 H. N- (3.3.diphenylprop-2-enyl)thiourea (C_) Yield: 81% o melting point: 201-203 C ^-NMR (DMSO- : 3 .81-4. 19 Dpm, multiolet , 2 . 1 H ; 6 6 . 12 ppm, triplet , J = 6 .3 Hz , 1 .0 H ; 6 .73-7 . 58 ppm , multiplet, 10.9 H ; 8.31 ppm , singlet , 2 . 1 H . N- (3.3-diphenylpropyl) thiourea (C 6 Yield: 93% melting point: 197-199°C H-NMR (CDC1 ) : 2.32 ppm, quartet, J = 7.2 Hz, 2.0 H; 3.13-3.60 ppm, multiplet, 2.0 H; 4.00 ppm, triplet, J = 7.2 Hz, 1.0H; 6.40 ppm, singlet, 2.0 H; 6.94-7.60 ppm, multiplet, 11.4 H. N-/2- (N 1 -benzyl-N'-phenyla ino)ethyl7-N"-cyano-S-methylisothiourea (C ? ) A solution of 15 g of N-benzyl 7 N-phenylethylenediamine in 100 ml of ether was added slowly to a stirred solution of N-cyanodimethyliminodithiocarbonate in 100 ml of ether. The resulting solution was stirred for 2 hours, after which the precipitate was filtered off, washed witn either and dried. Yield: 70 ', o melting point: 148-152 C ! H-NMR (CDC1 ) : 2.33 ppm, singlet, 2.6 H; 3.30-3.76 ppm, multiplet, 4.1 H; 4.55 ppm, singlet, 1.8 H; 6.59-6.95 ppm, multiplet, 3.4 H; 7.10-7.50 ppm, multiplet, 7.3H. N-cyano-S-methyl-N'- (2-/2-methyl-alpha- (2-ρyridyl)benzylthio7ethyl) isothiourea (C 1 A solution of 20 mg of 2 methylphenyl-2-pyridylmethanol and 11.4 g of cysteamine in 300 ml 48% HBr was refluxed for 5 hours and subsequently evaporated. The residue was dissolved in H O, brought at pH 11 with KOH, after which the aqueous phase was extracted with CHC1„. The CHCl,-layer was dried over MgSO and evaporated. 3 3 ^ 4 The residue was dissolved in ether and added slowly to a solution of 15 g of N-cyanodimethyliminodithiocarbonate. After stirring for 3 hours, the precipitate was filtered off, washed with ether and dried. Yield: 60% o melting point: 96-99 C. H-NMR (CDC1 ) : 2.34 ppm, singlet, 2.9 H; (2.56 ppm, singlet; 2.71 ppm, triplet, J = 6.3 Hz) together: 5.1 H; 3.51 ppm, quartet, J = 6.3 Hz, 2.0 H; 5.47 ppm, singlet, 1.0 H; 7.01-7.75 ppm, multiplet, 8.2 H; 8.47-8.64 ppm, multiplet, 0.9 H. General procedure for the synthesis of the σuanidines of examples_I-VI_and_VIII-X. A solution of 10 g of a thiourea (C -C ) and 1.2 equivalents of methyl iodide in 200 ml of methanol was stirred for 18 hours at room temperature. After evaporating the solvent, a solution of 2.5 g of 4- (3-aminopropy1) imidazole or 4- (2-aπinoethyl) imidazole in 200 ml of ethanol was added to the residue. The resultant mixture was refluxed for 70 hours and the product was purified by columnchromatography (silica gel 0.063-0.200 mm). General_procedure for_the synthesis of the guanidine derivatives of_examp_les_VII_and_XI. A solution of 12 g of the appropriate S-methyiisothiourea derivative (C or C ) and 2 .5 g of 4- (3-aminocroDyl) imidazole in 7 a 300 ml ethanol was refluxed for 70 hours. After evaporating the solvent the residue was applied to a silica column and eluted with 50% mixture of ethanol and chloroform. The fractions containing pure nitrile, were collected, the solvent was evaporated and the residue dissolved in 2 N HCl. After refluxing for 3 hours the reaction mixture was evaporated and the residue dissolved in methanol and added to a solution of picric acid in methanol. The precipitated oil was washed thoroughly with methanol and dried in vacuo on which the oil solidified. 5 E^SB.!:!.! N-/2- (diphenylmethylthio)ethyl7-N'-/3- (imidazole-4-yl)proρyl7 3 u §Didi2!?_-?i.} dr^genmale te Elution with ethanol. The compound was crystallized in the presence 10 of an excess of maleic acid from ethanol/ether. Yield: 12% melting point: 119-123 C H-NMR (DMSO-d : 1.82 ppm, quintet, J = 7.2 Hz, 2.0 H; 2.38-2.82 ppm, multiplet, (+DMSO-d ) , 6.0 H; 3.01-3.50 ppm, 15 multiplet, 4.0 H: 5.42 ppm, singlet, 1.0 H; 6.06 ppm, singlet, 4.0 H; 7.08-7.72 ppm, multiplet, 15.5 H; 3.35 ppm, doublet, J = 0.3 Hz, 0.9 H. Example II ~,c> N-/2- (diphenylmethylthio)ethyl7- '-/2-imidazole-4-yI)ethyl uanidine.dihydrogenmaleate Elution with a 50" mixture of ethyl acetate and ethanol. The compound was crystallized in the presence of an excess of maleic acid from ethanol/ether. 25 Yield: 22% melting point: 152-155 C. H-NMR (DMSO-d ) : 2.52 ppm, triplet. J = 5.9 Hz, (+DMSO-d ) , 3.0 H: 3.86 ppm, triplet, J = 5.9 Hz, 2.0 H; 3.10-3.64 ppm, multiplet, 4.0 H; 5.41 ppm, singlet, 1.0 H; 6.09 ppm, 30 singlet, 4.0 H; 7.16-7.72 ppm, multiplet, 15.4 H; 3.74 ppm, singlet 1.0 H. -13- Example III N-/2- (diphenylmethoxy)ethyl7-N'-/3- (imidazoie-4-yl)propyl7 guanidine. 3/S dihydroσenmaleate Elution with propanol-2 and crystallized in the presence of an excess of maleic acid from methanol/ether. Yield: 3% melting point: 132-135 C H-NMR (DMSO-dg) : 1.74 ppm, quintet, J = 7.2 Hz, 2.0 H; 2.60 ppm, triplet (+DMSO-d ^ ) , J = 7.2 Hz, 2.1 H; 3.00-3.60 ppm, multiplet (+H„0) 6.0 H; 5.46 ppm, singlet, 1.0 H; 6.02 ppm, singlet, 3,0 H; 7.G6-7.62 ppm, multiplet, 14.0 H; 8.76 ppm, singlet, 0.9 H. Exaπrole_iy N-^3- (imidazole-4-yl) propyl /-N' -2-/α-phenyl-4-methylbenzylthio — » — ethyl guanidine dipicrate Elution with a 50% mixture of ethyl acetate and ethanol. The product was crystallized in the presence of an excess of picric acid from methanol/H ^ O. Yield: 13% melting point: 76-73 C H-NMR (DMS0-d„) : 1.78 opm, quintet, 2.0 H; b 2.22 ppm, singlet, 3.OH; 2.31-2.74 ppm, multiplet, 11.0H(+DMSO-d_) 3.00-3.73 ppm, multiplet, 12.OH (H„0 ; 5.23 ppm, singlet, 1.0H; 6.90-7.53 ppm, multiplet, 11.4H; 8.52 ppm, singlet, 4.OH; 3.92 ppm, singlet, 1.2H; 14.22 ppm, singlet, 2.0 H. Example V 4-/2- (imidazole-4-yl) thyl7-N* -2-/α-phenyl-4-methylbenzylthio/ethyl guanidine . <3ihydrogen_maleate Elution with a 50% mixture of ethylacetate and propanol-2. The product was crystallized in the presence of an excess of maleic acid from propanol-2/ethylacetate. Yield: 32% melting point: 119-121 C. ! H-NMR (DMSO-d,.) : 2.24 ppm, singlet, 2.8H; 2.32-2.65 ppm , multiplet, 9.1 H t+DMSO-d,.) ; 2.80 ppm, triplet, J = 6.3 Hz, 2.OH; 3.14-3.62 ppm, multiplet, 3.8 H; 5.33 ppm, singlet, 1.0H; 6.05 ppm, singlet, 4.0H; 7.00-7.62 ppm, multiplet, 14.3 H; 8.63 ppm, singlet, 1 OH. ExamDle VI N-/2- (α-phenyl-4-fluorobenzylthio)ethyl/-N'-/3-(imidazole-4-yl) prσpyl7guanidine. dihydrogenoxalate Elution with a 50% mixture of ethylacetate and propanol-2. The compound was crystallized in the presence of an excess of oxalic acid from m thanol/ethylacetate. Yield: 15% melting point: 33-35°C 1 H-NMR: (dioicrate; DMSO-d ) 1.70-1.96 Dpm, quintet, 6 J = 6.9 Hz, 1.9H; 2.34-2.90 ppm, multiplet, (+DMSO-d_.) , 5.1H; 3.00-3.53 ppm, multiplet, 4.0H; 5.43 ppm, singlet, 1.0H: 7.00-7.37 ppm, multiplet, 15.4 H; 8.60 ppm, singlet, 3.9 H: 9.03 ppm, doublet, J = 0.8 Hz, 0.8 H: 14.05 ppm. singlet (b) 2.1 H. Example VII N-/3- (imidazole-4-yl)propyl7-N'- (2-/2-methyl-alpha- (2-pyridyl) benzylthio7ethy1)guanidine. tripicrate Yield: 5% melting point: 98-102 C H-NMR (DMSO-d ) ; 1.82 ppm, quintet, J = 7.0 Hz, 2.0H; 2.38 ppm, singlet, 3.OH; 2.45-2.83 ppm, multiplet, (+DMSO-d ) , 7.8 H; 3.02-3.60 ppm, multiplet, 4.OH; 5.63 ppm, singlet, 1.0H; 7.03-3.83 ppm, multiplet, 19.OH; 9.03 ppm, singlet, 1.0H; 14.02 ppm, singlet (b) , 2.OH. Example_VIII N- (3.3-diphenylpropyl) -N'-/2- (imidazole-4-yl)ethyl7 guanidine. dihydrogen maleate. Elution with a 50% mixture of ethvlacetate and ethanol. The product was crystallized in the presence of an excess of maleic acid from propanol-2/ethylacetate. Yield: 32% o melting point: 115-118 C H-NMR (D O) : 2.33 ppm, quartet, J = 7..3 Hz, 2.OH; 2.94 ppm, triplet, J = 7.1Hz, 2.OH; 3.16 ppm, triplet, J = 7.1 Hz, 2.OH; 3.41 ppm, triplet, J = 7.1 Hz, 2.OH; 4.03 ppm, triplet, J = 7.3 Hz, 1.0H; 6.34 ppm, singlet, 4.3H; 7.15-7.44 ppm, multiplet, 10.5H; 3.56 ppm, doublet, J = 1.2 Hz, 0.3 H. Examole_IX_ N- (3.3-diphenylpropyl) -N'-/3- (irnidazole-4-yi)propyl7guanidine. dipicrate Elution with a 50% mixture of ethylacetate and ethanol. The product was crystallized in the presence of an excess of picric acid from propano1-2/ether. Yield: 12% melting point: 73-77 C. H-NMR (DMSO-dg) : 1.78 ppm, quintet, J = 7.5 Hz, 2.0H; (2.32 ppm, triplet, J = 7.5 Hz,- 2.63 ppm, triplet, SUBSTITUTE SHEET J = 7.5 Hz) together (+DMSO-d ) 8.3 H; 2.87-3.30 opm, 5 multiplet, 4.0H; 4.00 ppm, triplet, J = 7.5H ^ , l.OH; (7.28 ppm, singlet: 7.43 ppm, singlet) together 16.2H; 8.60 ppm, singlet, 4.OH; 9.00 ppm, doublet, J = 0.8 Hz, l.OH; 14.13 ppm, singlet (b) . 2.OH. Example X N(3.3-diphenylprop-2-enyl) -N'-/3-imidazole-4-yl) propyl7 guanidine. Hi Crystallized from ethanol/diethylether. Yield: 10% melting point: 73-76 C. H-NMR (DMSO-d..) : 1.30 ppm, quintet, J = 7.0 Hz, 2.0H; 2.39-2.80 ppm, multiplet, (+DMSO-d ) 4.1H; 2.94-3.37 ppm, multiplet, 2.OH; 2.84 ppm, triplet, J = 7.0 Jz, 2.OH; 6.13 ppm, triplet, J = 7.0 Hz, l.OH; 7.00-3.2Q ppm. multiplet, 16.5 H: 3.35 ppm, singlet, l.OH. Example_XI N-/2- (N 1 -benzyl-N'-ph nylamino) ethyl/-N"-/3- (imidazole-4-yl) propyl7guanidine, tripicrate Yield: 6% 1 H-NMR (DMSO-d 6 ) : 1.80 ppm, quintet, J = 7.0 Hz, 2.0H; 2.42-2.85 ppm, multiplet, (+DMSO-d ) 4.4 H+ 2.97-377 ppm, multiplet (+H_0) 6.6 H; 4.62 ppm, singlet, 2.OH; 6.41-7.74 ppm, multiplet, 17.OH; 8.64 ppm, singlet, 6.OH; 9.03 ppm, singlet, l.OH; 14.20 ppm, singlet (b) , 2.OH. SUBSTITUTE SHEET

Claims: CLAIMS: 1. N- (2-substituted alkyl)-N'-/ (irnidazole-4-yl) alkyl) 7g andine characterized in that it has the formula 1, wherein m is 1, 2 or 3,- n is 2 or 3 X is a) S.O or CH_, and Y is a R substituted diphenylmethyl group or (10, 11- dihydro) 5H-dibenzo-/a-d7-cycloheptene-5-yl group, or is b) N , wherein 1 γ ι Y is a R-substituted phenyl group and Y is also a R-substituted phenyl group in that Y and Y need not be substituted simultaneously or Y is a R-substituted benzyl group, or is c) =CH-, and Y is a R-substituted diDhenylmethvlid nvl αrouc or- (10, 11-dihydro)-5H-dibenzo-/a,d/-cyclohepter.e-5-yiidene group, R is H, alkyl, alkoxy, halogen and/cr trihalogen methyl, with the understanding that from all the appropriate phenyl rings one or more may be substituted by a R-substituted heterocyclic aromatic ring and their acid addition salts. 2. Compound according to claim 1, characterized in that n = 3. 3. Compound according to claim 1, characterized in that X is a sulphur atom. 4. Compound according to claim 1, characterized in that m is 2. 5. Compound according to claim 3, characterized in that X is =CH-. SUBSTITUTE SHEET 6. Compound according to claim 1 , characterized in that X is N I Y l 7. Compound according to claim 1, characterized in that R is hydrogen. 8. Process for the preparation of a compound according to claim 1, characterized in that a primary amine of the formula R NH„ , wherein R - corresponds with the appropriate group Y-X- (CH ) of formula 1, is reacted with benzovlisothiocyanate ^ m to a benzoylthiourea derivative, followed by hydrolysis of this derivative to the corresponding thiourea, converting this thiourea with methyliodide into an isothiouerea and producing the desired compound by reaction with aminopropylimidazole or aminoethylimidazole ^ and possibly converting said compound int,o an acid addition salt or producing the free compound from such an obtained salt. 9. Process for the preparation of a compound according to claim 1, characterized in that a compound having a basic group in the substituent to the N'-alkyl group is prepared, by reacting a primary amine of the formula R NH , wherein R corresponds with the appropriate group Y-X- (CH ) of formula 1, with dimethylcvano 2 m iminodithiocarbamate to a N-cyano isothiourea, followed by reaction of this N-cyano isothiourea with aminopropylimidazole to the cyano guanidine and producing by hydrolysis the desired compound and possibly converting said compound into an acid addition salt, or producing the free compound from such an obtained salt. SUBSTITUTE SHEET ' ■ f- 10. Pharmaceutical composition for the treatment of congestive heart failures and some allergic conditions, characterized in that the composition comprises at least one compound of the formula 1, as defined in claims 1-7 or an acid addition salt thereof, as an active substance. 11. Process for preparing a pharmaceutical composition according to claim 10, characterized in that therefore a compound according to one of claims 1-7 is used. SUBSTITUTE SHEET

Inventors: STERK GEERT JAN, TIMMERMAN HENK, VAN DER GOOT HENK, STERK, GEERT, JAN, TIMMERMAN, HENK, VAN DER GOOT, HENK
Applicants: CEDONA PHARM BV, CEDONA PHARMACEUTICALS B.V.
Application year: 1987
Main classification: C07D233
IPC codes: A61K31, A61P1, A61P9, A61P37, A61P43, C07D233, C07D401, C07D407, C07D417